Entry of biomarker-driven targeted emerging therapies like Anlotinib, ADP-A2M4, Letetresgene autoleucel set to significantly boost the Synovial Sarcoma Market
LAS VEGAS, March 3, 2021 /PRNewswire/ -- DelveInsight's "Synovial Sarcoma Market" report provides a thorough comprehension of the Synovial Sarcoma, historical and forecasted epidemiology, and the Synovial Sarcoma market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Synovial Sarcoma market report also proffers an analysis of the current and emerging Synovial Sarcoma treatment landscape, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the Synovial Sarcoma Market Research Report
- As Synovial Sarcoma is a chemo-sensitive tumor, the first-line treatment includes single-agent or combination chemotherapy. Doxorubicin, an anthracycline antibiotic, is generally considered the most active single agent in producing objective responses in sizeable clinical trial settings. Doxorubicin with or without ifosfamide remains the mainstay of first-line chemotherapy for Synovial Sarcoma treatment.
- The frontline treatment options have remained unchanged for years, now challenged by targeted therapies in the pipeline.
- Ifosfamide is the favored second-line treatment option. Other alternative options include YONDELIS (Trabectedin) and Pazopanib (VOTRIENT), administered when patients relapse or fail to respond to first-line treatment options. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide.
- Prominent players such as Pharma Mar SA, Johnson and Johnson, Novartis Pharmaceuticals, Advenchen Laboratories, Adaptimmune Therapeutics, GlaxoSmithKline, Epizyme Inc., OncoTherapy Science, BioAtla, Takara Bio, Eli Lilly and Company, and many others are involved in developing Synovial Sarcoma therapies.
- Targeting the MAGE-A4 biomarker is a popular strategy, with two different assets showing early promising activity. ADP-A2M4andLetetresgene Autoleucel have been granted FDA Breakthrough Therapy Designation in MAGE-A4 expressing patients.
- The Synovial Sarcoma market is expected to show positive growth, mainly ascribed to the increased prevalence and the anticipated launch of novel therapies, such as Anlotinib, ADP-A2M4, Letetresgene Autoleucel, and others during the forecast period of 2018-2030.
For further information on Market Impact by Therapies, visit: Synovial Sarcoma Therapeutic Market
Synovial Sarcoma, also known as malignant synovioma, can originate from different soft tissue types, such as muscle or ligaments. It is a high-grade tumor and spreads to distant sites. Synovial Sarcoma symptoms depend on where the tumor forms. The disease is often first noticed as a painless lump. If it is near a nerve, it might cause pain or numbness as it grows.
As per DelveInsight's analysts, the total Synovial Sarcoma incident population in the 7MM was estimated to be 1,610 cases in 2020. The males appear to have a predisposition to Synovial Sarcoma, which is why a higher percentage of incidence was observed in males than females in the United States.
The Synovial Sarcoma Market Report provides historical as well as forecasted epidemiological analysis segmented into:
- Incident Cases
- Gender-Specific Cases
- Age-Specific Cases
- Location-Specific Cases
- Stage-Specific Cases
Get a sample copy of this report: Global Synovial Sarcoma Market Landscape
Synovial Sarcoma Treatment Market
The primary treatment for Synovial Sarcoma is surgery to eliminate the entire tumor with clear margins when possible. Radiotherapy may also be used, either before or after surgery, to decrease the risk of leaving cells behind.
Chemotherapy (typically Doxorubicin and/or Ifosfamide) is recommended in the Synovial Sarcoma treatment as the tumor is highly chemo-sensitive. Single-agent or combination chemotherapy are options for the first-line treatment of Synovial Sarcoma. Doxorubicin, an anthracycline antibiotic, is generally considered the most active single agent producing objective responses in sizeable clinical trial settings. Doxorubicin with or without ifosfamide remains the mainstay of first-line chemotherapy for Synovial Sarcoma treatment. However, data from recent studies suggest that Synovial Sarcoma patients can benefit from a first-line combination treatment of ifosfamide with doxorubicin over monotherapy doxorubicin. However, due to the disease's rarity, this cannot be considered a conclusive result.
On the other hand, ifosfamide has the advantage of having no dose-limiting cumulative toxicity. Ifosfamide (in high doses) is the favored second-line treatment option as it shows activity in Synovial Sarcoma patients. Other alternative options for second-line treatment include YONDELIS (Trabectedin) and Pazopanib (VOTRIENT), administered when patients relapse or fail to respond to first-line treatment options. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. Biomarker-driven approvals are set to transform the treatment landscape.
Synovial Sarcoma Emerging Therapies Along with Key Players
- Anlotinib (AL3818): Advenchen Laboratories
- ADP-A2M4: Adaptimmune Therapeutics
- Letetresgene autoleucel: GlaxoSmithKline
And several others.
Other Synovial Sarcoma Drugs in Development
- Tazemetostat: Epizyme, Inc.
- OTSA101: OncoTherapy Science
- CAB-AXL-ADC: BioAtla
- TBI-1301: Takara Bio
- Ramucirumab: Eli Lilly and Company
And several others.
Concluding thoughts on Synovial Sarcoma Market Growth Dynamics
Synovial Sarcoma Market Drivers
- Development of Personalized Therapy - Personalized therapy can be offered at a premium and help the company attain high profits. Multiple biomarkers are associated with synovial sarcoma and are under investigation regarding their pathways and mechanisms of action.
- Pathophysiology well known - The extensive research is done that helped study pathophysiology extensively, which can be utilized to develop new drugs.
- Increase in the number of research initiatives - Several targeted therapies like Letetresgene autoleucel, which is a Phase II drug, and ADP-A2M4 under a Phase II drug, and among others, will help drive the Synovial Sarcoma market.
Synovial Sarcoma Market Barriers
- The rarity of disorder - The incidence of synovial sarcoma is very low and rare, which means a small patient is targetted.
- Lack of understanding and cell lines - A lack of specific guidelines for this disease can prove to be a detriment to treat this cancer.
- Cost of treatment - High costs cause a substantial economic burden for patients, resulting in non-compliance. Therefore companies should have a product that is effective and economically viable for patients.
Scope of the Synovial Sarcoma Market Insight Report
- Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
- Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
- Synovial Sarcoma Markets Segmentation: By Geographies and By Synovial Sarcoma Therapies (Historical and Forecasted, Current and Upcoming)
- Leading Market Companies investigating its candidates for Synovial Sarcoma: Pharma Mar SA, Johnson and Johnson, Novartis Pharmaceuticals, Advenchen Laboratories, Adaptimmune Therapeutics, GlaxoSmithKline, Epizyme Inc., OncoTherapy Science, BioAtla, Takara Bio, Eli Lilly and Company, and several others.
- Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Global Synovial Sarcoma Treatment Market Size
Table of Contents
1 | Key Insights |
2 | Report Introduction of Synovial Sarcoma |
3 | Synovial Sarcoma Market Overview at a Glance |
4 | Executive Summary of Synovial Sarcoma |
5 | Synovial Sarcoma Disease Background and Overview |
6 | Synovial Sarcoma Epidemiology and Patient Population |
7 | The United States Synovial Sarcoma Epidemiology |
8 | EU5 Synovial Sarcoma Epidemiology |
8.1 | Germany Epidemiology |
8.2 | France Epidemiology |
8.3 | Italy Epidemiology |
8.4 | Spain Epidemiology |
8.5 | United Kingdom Epidemiology |
9 | Japan Synovial Sarcoma Epidemiology |
10 | Synovial Sarcoma Patient Journey |
11 | Case Reports of Synovial Sarcoma |
12 | Synovial Sarcoma Marketed Products |
12.1 | YONDELIS (Trabectedin): Pharma Mar SA/Johnson and Johnson |
12.2 | VOTRIENT (Pazopanib): Novartis Pharmaceuticals |
13 | Synovial Sarcoma Emerging Therapies |
13.1 | Key Cross Competition |
13.2 | Anlotinib (AL3818): Advenchen Laboratories |
13.3 | ADP-A2M4: Adaptimmune Therapeutics |
13.4 | GSK3377794 (NY-ESO-1 T cells): GlaxoSmithKline |
14 | Other Synovial Sarcoma Drugs in Development |
14.1 | Tazemetostat: Epizyme, Inc. |
14.2 | OTSA101: OncoTherapy Science |
14.3 | CAB-AXL-ADC: BioAtla |
14.4 | TBI-1301: Takara Bio |
14.5 | Ramucirumab: Eli Lilly and Company |
15 | Synovial Sarcoma 7MM Market Analysis |
16 | The United States Synovial Sarcoma Market Size |
17 | EU-5 countries Synovial Sarcoma Market Size |
17.1 | Germany Market Size |
17.2 | France Market Size |
17.3 | Italy Market Size |
17.4 | Spain Market Size |
17.5 | The United Kingdom Market Size |
18 | Japan Synovial Sarcoma Market Size |
19 | KOL Views |
20 | Synovial Sarcoma Market Drivers |
21 | Synovial Sarcoma Market Barriers |
22 | Synovial Sarcoma SWOT Analysis |
23 | Synovial Sarcoma Unmet Needs |
24 | Synovial Sarcoma Market Access |
25 | Appendix |
26 | DelveInsight Capabilities |
27 | Disclaimer |
28 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Synovial Sarcoma Market Size Report
View Related Reports
- Synovial Sarcoma Epidemiology Forecast Analysis
DelveInsight's Synovial sarcoma (SS) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Synovial sarcoma (SS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Synovial Sarcoma Pipeline Analysis
Synovial Sarcoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Synovial Sarcoma market.
- Kaposi's Sarcoma Market Analysis
DelveInsight's Kaposi's Sarcoma Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of the disease & an understanding of historical and forecasted epidemiology.
- Soft Tissue Sarcoma Market Analysis
DelveInsight's Soft Tissue Sarcoma Market report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
- Marfan Syndrome Market Analysis
DelveInsight's 'Marfan Syndrome- Market Insights, Epidemiology and Market Forecast- 2030' report delivers a full understanding of the Marfan Syndrome, historical and forecasted epidemiology.
- Partial Paralysis Market Analysis
DelveInsight's 'Partial Paralysis Market Insights, Epidemiology and Market Forecast- 2030' report delivers a full understanding of historical and forecasted epidemiology.
- Echocardiography Devices Market Insights, Competitive Landscape and Market Forecast Analysis
Echocardiography Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Echocardiography Devices.
- Blood Glucose Monitoring Systems Market
Blood Glucose monitoring systems Market Insights, Competitive Landscape, and Market Forecast-2025 report deliver an in-depth understanding of Blood Glucose monitoring systems.
- Arteriotomy Closure Devices Market Analysis
Arteriotomy Closure Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Arteriotomy Closure Devices and the historical and forecasted epidemiology.
- Coronary Pressure Market Analysis
Coronary Pressure Market Insights, Competitive Landscape, and Market Forecast-2025 report deliver an in-depth understanding of Coronary Pressure and the historical and forecasted epidemiology.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
